Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Prolyl-Hydroxylase Inhibitors to Activate Hypoxia-Inducible Factor (HIF) as a Novel Therapeutic Approach in CKD
Hypoxia-inducible factor (HIF) is a heterodimeric transcription factor composed of an oxygen-dependent α-subunit and constitutively expressed β subunit, which plays a central role in cellular adaptation to hypoxia by transcriptionally upregulating its target genes involved in angiogenesis, erythropo...
Saved in:
Main Authors: | Tetsuhiro Tanaka (Author), Masaomi Nangaku (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2009-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Neuroprotective Effect of HIF Prolyl Hydroxylase Inhibition in an In Vitro Hypoxia Model
by: Maria Savyuk, et al.
Published: (2020) -
Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Development of Drugs on Endothelial Cell Protection for Overcoming CKD
by: Keisuke Ishizawa, et al.
Published: (2009) -
HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons
by: Andrey A. Poloznikov, et al.
Published: (2021) -
Bibliometric analysis of hypoxia inducible factor prolyl hydroxylase inhibitor in anemia
by: Li Zheng, et al.
Published: (2022) -
Drug Discovery for Overcoming Chronic Kidney Disease (CKD): New Therapy for CKD by a (Pro)Renin-Receptor-Blocking Decoy Peptide
by: Atsuhiro Ichihara, et al.
Published: (2009)